<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03843372</url>
  </required_header>
  <id_info>
    <org_study_id>201601844B0</org_study_id>
    <nct_id>NCT03843372</nct_id>
  </id_info>
  <brief_title>High Flow Nasal Cannula for Obstructive Sleep Apnea</brief_title>
  <official_title>High Flow Nasal Cannula Compared to Continuous Positive Airway Pressure in the Treatment of Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chung-Chieh, Yu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compare the efficacy of high flow nasal cannula with nasal continuous positive&#xD;
      airway pressure. All of participants will be randomized to receive one night high flow nasal&#xD;
      cannula therapy and another night for nasal continuous positive airway pressure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obstructive sleep apnea-hypopnea syndrome (OSAHS) is a common medical condition. Nasal&#xD;
      continuous positive airway pressure (CPAP) is mainstay of treatment for OSAHS, but CPAP has&#xD;
      some limitations. Patient who has bulbar dysfunction and poor consciousness are&#xD;
      contraindications for CPAP. They are also not suitable for other therapy. There are still&#xD;
      large number of patients could not accept CPAP. Alternative treatment method transnasal high&#xD;
      flow was developed and previous study showed moderately reduce respiratory event. It is&#xD;
      deliver 20 L/minute constant room air by nasal cannula. Because the technical limitation, the&#xD;
      maximal flow rate is also 20 L/minute and it limit the effectiveness.&#xD;
&#xD;
      Recently, new high flow nasal cannula(HFNC) is developed. This HFNC has already widely been&#xD;
      used for respiratory disease. It can deliver air flow up to 60 L/mins. It is also can&#xD;
      maintain high humidifier and adequate temperature. The every 10 L/min air flow could generate&#xD;
      approximately 1 cmH2O positive end expiratory pressure (PEEP). The higher air flow could&#xD;
      generate more high PEEP and may have better effect than previous HFNC, but there are no study&#xD;
      to evaluate the efficacy in OSAHS patient. Thus, the purpose of our study is to compare the&#xD;
      efficacy of HFNC with standard CPAP therapy.&#xD;
&#xD;
      All of the participants were randomized into two groups for minimized first night effects.&#xD;
      All of them would receive one-night HFNC therapy and another night for CPAP titration under&#xD;
      PSG monitoring. The duration between these two treatments was approximately one week apart.&#xD;
      The first group underwent CPAP titration on the first night and HFNC titration on the second&#xD;
      night. Conversely, the second group was subjected to HFNC on the first night and CPAP&#xD;
      titration on the second night. All of the participants were asked and recorded their side&#xD;
      effects following completion of an HFNC or CPAP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 30, 2017</start_date>
  <completion_date type="Actual">March 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>All of participants will be randomly allocated into two groups as random number table. The first group will ongoing CPAP therapy in first night and high flow nasal cannula in the second night. The second group will oppositely performed high flow nasal cannula in first night and CPAP in second night.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apnea Hypopnea Index</measure>
    <time_frame>2 days</time_frame>
    <description>The Apnea Hypopnea Index(AHI) is an index used to indicate the severity of sleep apnea. It is represented by the number of apnea and hypopnea events per hour of sleep. The AHI under one night transnasal high flow therapy will be compared with one night continuous positive airway pressure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxygen Desaturation Index</measure>
    <time_frame>2 days</time_frame>
    <description>The oxygen desaturation index (ODI) is the number of times per hour of sleep that the blood's oxygen level drop by 3% degree from baseline.The ODI under one night transnasal high flow therapy will be compared with one night continuous positive airway pressure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Sleep Time</measure>
    <time_frame>2 days</time_frame>
    <description>The total amount of sleep time spent during a study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Efficiency</measure>
    <time_frame>2days</time_frame>
    <description>Sleep efficiency is the percentage of the total time spent asleep compared to the total amount of recording time.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>First night HFNC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first night will receive high flow nasal cannula (HFNC) therapy and the second night accept continuous positive airway pressure (CPAP) therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First night CPAP group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In contrast, the first night will receive continuous positive airway pressure and the second accept high flow nasal cannula therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High flow nasal cannula</intervention_name>
    <description>All of participants will be received one night high flow nasal cannula and another night for continuous positive airway pressure.</description>
    <arm_group_label>First night CPAP group</arm_group_label>
    <arm_group_label>First night HFNC group</arm_group_label>
    <other_name>continuous positive airway pressure</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Apnea hypopnea index greater than 5 times per hour&#xD;
&#xD;
          -  Age greater than 18 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Central sleep apnea&#xD;
&#xD;
          -  Hypoventilation syndrome&#xD;
&#xD;
          -  Chronic obstructive airway disease&#xD;
&#xD;
          -  Receive soft palate surgery or used an oral appliance&#xD;
&#xD;
          -  Intolerance to transnasal high flow or CPAP&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Unstable hemodynamic state&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status higher than grade 2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sleep center</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang-Gung Memorial Hospital, Keelung</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sleep center</name>
      <address>
        <city>Keelung</city>
        <zip>204</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 9, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2019</study_first_posted>
  <results_first_submitted>August 3, 2020</results_first_submitted>
  <results_first_submitted_qc>November 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 17, 2020</results_first_posted>
  <last_update_submitted>November 22, 2020</last_update_submitted>
  <last_update_submitted_qc>November 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Chung-Chieh, Yu</investigator_full_name>
    <investigator_title>Director of Sleep Center</investigator_title>
  </responsible_party>
  <keyword>Continuous Positive Airway pressure</keyword>
  <keyword>High Flow Nasal Cannula</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified participants raw data will be made available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will available within 12 months of study completion</ipd_time_frame>
    <ipd_access_criteria>Requestors need application and explain the purpose. The data access will be provided after approved by review panel.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 8, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT03843372/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HFNC First, Then CPAP</title>
          <description>Participants first received high flow nasal cannula (HFNC) for one night. After a washout period of one week, they then received continuous positive airway pressure (CPAP) for one night.</description>
        </group>
        <group group_id="P2">
          <title>CPAP First, Then HFNC</title>
          <description>Participants first received continuous positive airway pressure (CPAP) for one night. After a washout period of one week, they then received high flow nasal cannula (HFNC) for one night.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>First Night HFNC Group</title>
          <description>The first night will receive high flow nasal cannula (HFNC) therapy and the second night accept continuous positive airway pressure (CPAP) therapy.</description>
        </group>
        <group group_id="B2">
          <title>First Night CPAP Group</title>
          <description>The first night will receive continuous positive airway pressure(CPAP) and the second accept high flow nasal cannula(HFNC) therapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" lower_limit="43.75" upper_limit="60.75"/>
                    <measurement group_id="B2" value="53.5" lower_limit="40.5" upper_limit="62"/>
                    <measurement group_id="B3" value="53.5" lower_limit="42.25" upper_limit="60.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>BMI(body mass index)</description>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.1" lower_limit="25.47" upper_limit="34.2"/>
                    <measurement group_id="B2" value="26.95" lower_limit="23.03" upper_limit="27.63"/>
                    <measurement group_id="B3" value="27.4" lower_limit="24.1" upper_limit="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Neck circumference</title>
          <units>cm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.5" lower_limit="36.88" upper_limit="45"/>
                    <measurement group_id="B2" value="37.5" lower_limit="35.63" upper_limit="40.75"/>
                    <measurement group_id="B3" value="38.5" lower_limit="36.13" upper_limit="42.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AHI</title>
          <description>Apnea hypopnea index (AHI) was represented by the number of apnea and hypopnea events per hour of sleep. An apnea is defined as a drop in the peak signal excursion by 90% of the pre-event baseline, and the duration of the 90% drop in sensor signal is 10 seconds. Events are considered hypopneas when the peak signal excursions drop by 30% of the pre-event baseline, and the duration of the 30% drop in signal excursion occurs for at least 10 seconds. Hypopneas are generally associated with a 3% oxygen desaturation or cause electroencephalogram arousal.</description>
          <units>events per hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.65" lower_limit="19.23" upper_limit="65.38"/>
                    <measurement group_id="B2" value="26.9" lower_limit="17.48" upper_limit="50.55"/>
                    <measurement group_id="B3" value="34.9" lower_limit="18.68" upper_limit="56.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>DI</title>
          <description>The desaturation index (DI) was the average number of desaturation episodes per hour. Desaturation episodes were defined as a decrease in the mean oxygen saturation of ≥3% from the pre-event baseline.</description>
          <units>events per hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.15" lower_limit="11.18" upper_limit="69.1"/>
                    <measurement group_id="B2" value="24.45" lower_limit="12.33" upper_limit="49.53"/>
                    <measurement group_id="B3" value="29.4" lower_limit="12" upper_limit="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sleep efficiency</title>
          <description>Sleep efficiency was the percentage of the total time spent asleep compared to the total amount of recording time.</description>
          <units>%</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.7" lower_limit="63.58" upper_limit="87.45"/>
                    <measurement group_id="B2" value="80.4" lower_limit="78.18" upper_limit="83.23"/>
                    <measurement group_id="B3" value="80.4" lower_limit="77.38" upper_limit="85.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total sleep time</title>
          <description>The total amount of sleep time spent during a study period.</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="324" lower_limit="271" upper_limit="350"/>
                    <measurement group_id="B2" value="331.65" lower_limit="315.53" upper_limit="346"/>
                    <measurement group_id="B3" value="330.15" lower_limit="301.3" upper_limit="346.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Apnea Hypopnea Index</title>
        <description>The Apnea Hypopnea Index(AHI) is an index used to indicate the severity of sleep apnea. It is represented by the number of apnea and hypopnea events per hour of sleep. The AHI under one night transnasal high flow therapy will be compared with one night continuous positive airway pressure.</description>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CPAP</title>
            <description>The polysomnography data of 28 participants treated with one night CPAP.</description>
          </group>
          <group group_id="O2">
            <title>HFNC</title>
            <description>The polysomnography data of 28 participants received one night HFNC therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Apnea Hypopnea Index</title>
          <description>The Apnea Hypopnea Index(AHI) is an index used to indicate the severity of sleep apnea. It is represented by the number of apnea and hypopnea events per hour of sleep. The AHI under one night transnasal high flow therapy will be compared with one night continuous positive airway pressure.</description>
          <units>events per hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.15" lower_limit="2.63" upper_limit="8.28"/>
                    <measurement group_id="O2" value="14.85" lower_limit="6.85" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The AHI was not a normal distribution. In the event that no carry over effect was detected between interventions, a Wilcoxon rank sum test was to be used to compare AHI between CPAP and HFNC</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oxygen Desaturation Index</title>
        <description>The oxygen desaturation index (ODI) is the number of times per hour of sleep that the blood's oxygen level drop by 3% degree from baseline.The ODI under one night transnasal high flow therapy will be compared with one night continuous positive airway pressure.</description>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CPAP</title>
            <description>The polysomnography data of 28 participants treated with one night CPAP.</description>
          </group>
          <group group_id="O2">
            <title>HFNC</title>
            <description>The polysomnography data of 28 participants received one night HFNC therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygen Desaturation Index</title>
          <description>The oxygen desaturation index (ODI) is the number of times per hour of sleep that the blood's oxygen level drop by 3% degree from baseline.The ODI under one night transnasal high flow therapy will be compared with one night continuous positive airway pressure.</description>
          <units>events per hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="0.4" upper_limit="4"/>
                    <measurement group_id="O2" value="5.25" lower_limit="2.08" upper_limit="21.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The oxygen desaturation index was not a normal distribution. In the event that no carry over effect was detected between interventions, a Wilcoxon rank sum test was to be used to compare oxygen desaturation index between CPAP and HFNC</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Sleep Time</title>
        <description>The total amount of sleep time spent during a study period.</description>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CPAP</title>
            <description>The polysomnography data of 28 participants treated with one night CPAP.</description>
          </group>
          <group group_id="O2">
            <title>HFNC</title>
            <description>The polysomnography data of 28 participants received one night HFNC therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Sleep Time</title>
          <description>The total amount of sleep time spent during a study period.</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="343" lower_limit="333.25" upper_limit="366.5"/>
                    <measurement group_id="O2" value="292.75" lower_limit="265.63" upper_limit="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The total sleep time was not a normal distribution. In the event that no carry over effect was detected between interventions, a Wilcoxon rank sum test was to be used to compare total sleep time between CPAP and HFNC</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Efficiency</title>
        <description>Sleep efficiency is the percentage of the total time spent asleep compared to the total amount of recording time.</description>
        <time_frame>2days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CPAP</title>
            <description>The polysomnography data of 28 participants treated with one night CPAP.</description>
          </group>
          <group group_id="O2">
            <title>HFNC</title>
            <description>The polysomnography data of 28 participants received one night HFNC therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Efficiency</title>
          <description>Sleep efficiency is the percentage of the total time spent asleep compared to the total amount of recording time.</description>
          <units>percentage of sleep time</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.1" lower_limit="80.15" upper_limit="90.43"/>
                    <measurement group_id="O2" value="74.25" lower_limit="65.8" upper_limit="80.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The sleep efficiency was not a normal distribution. In the event that no carry over effect was detected between interventions, a Wilcoxon rank sum test was to be used to compare sleep efficiency between CPAP and HFNC</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 days; All of the participants were asked and recorded their side effects following completion of an HFNC or CPAP.</time_frame>
      <desc>CPAP and HFNC have been widely used in clinical practice for long time, but the serious adverse effects or mortality events are rarely reported . Our study excluded the participants who have unstable clinical condition. Therefore, there was no serious adverse events or mortality in our study.</desc>
      <group_list>
        <group group_id="E1">
          <title>CPAP</title>
          <description>The polysomnography data of 28 participants received one night CPAP therapy.</description>
        </group>
        <group group_id="E2">
          <title>HFNC</title>
          <description>The polysomnography data of 28 participants received one night HFNC therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Frequent awakenings</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nasal stuffiness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>dry nose or throat</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Too strong airflow</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>CPAP Mask or HFNC cannula discomfort</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Too hot airflow</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Chung-Chieh Yu</name_or_title>
      <organization>Sleep Center, Chang Gung Memorial Hospital, Keelung, Taiwan</organization>
      <phone>886+22432-9292 ext 2658</phone>
      <email>terminatorchieh@yahoo.com.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

